Targets › LRAT
1 program from 1 company in 3 trials: 2 Phase 2, 1 Phase 3; Ophthalmology; next expected readout Jun 2028.
Transfers the acyl group from the sn-1 position of phosphatidylcholine to all-trans retinol, producing all-trans retinyl esters. Retinyl esters are storage forms of vitamin A (Probable). (UniProt, O95237)
Open in Phaseline: the race on LRAT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Alkeus Pharmaceuticals | ALK-001 Deuterated vitamin A analog that slows production of lipofuscin and related retinoid bypro | LRAT | Phase 3 | Stargardt Disease | Jun 2028 |
Stargardt Disease (3)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.